Free Trial
→ Why Some AI Stocks Already Surged Over 300 Percent (From Brownstone Research) (Ad)tc pixel Free TRDA Stock Alerts

Entrada Therapeutics (TRDA) Financials

Entrada Therapeutics logo
$4.37 -0.41 (-8.58%)
Closing price 04:00 PM Eastern
Extended Trading
$4.40 +0.03 (+0.76%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Entrada Therapeutics

Annual Income Statements for Entrada Therapeutics

This table shows Entrada Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -51 -97 -6.69 65 -143
Consolidated Net Income / (Loss)		 -27 -51 -95 -6.69 66 -144
Net Income / (Loss) Continuing Operations		 -26 -51 -95 -6.69 66 -144
Total Pre-Tax Income 		-26 -51 -95 12 66 -143
Total Operating Income		 -27 -51 -97 -3.16 47 -158
Total Gross Profit		 0.00 0.00 0.00 129 211 25
Total Revenue		 0.00 0.00 0.00 129 211 25
Operating Revenue		 - - 0.00 129 211 25
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 27 51 97 132 164 183
Selling, General & Admin Expense		 5.57 15 31 32 38 41
Research & Development Expense		 21 36 67 100 125 142
Total Other Income / (Expense), net		 0.29 -0.03 2.63 15 19 15
Interest Expense		 -0.14 - - - -19 -15
Income Tax Expense		 - - 0.00 19 0.86 0.92
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.00 2.06 - 0.24 -0.70
Basic Earnings per Share		 ($24.00) ($8.16) ($3.02) ($0.20) $1.76 ($3.47)
Weighted Average Basic Shares Outstanding		 1.11M 6.27M 31.29M 33.05M 37.31M 41.37M
Diluted Earnings per Share		 ($24.00) ($8.16) ($3.02) ($0.20) $1.68 ($3.47)
Weighted Average Diluted Shares Outstanding		 1.11M 6.27M 31.29M 33.05M 39.00M 41.37M
Weighted Average Basic & Diluted Shares Outstanding		 - 31.25M 33.08M 33.60M 37.59M 38.28M

Quarterly Income Statements for Entrada Therapeutics

This table shows Entrada Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -10 23 55 -14 1.21 -17 -43 -44 -38 -40 -43
Consolidated Net Income / (Loss)		 -9.54 23 55 -14 1.13 -17 -43 -44 -39 -40 -43
Net Income / (Loss) Continuing Operations		 -9.54 23 55 -14 1.13 -17 -43 -44 -39 -40 -43
Total Pre-Tax Income 		9.20 25 58 -16 -0.74 -17 -43 -43 -39 -40 -43
Total Operating Income		 4.91 21 53 -22 -5.87 -22 -47 -47 -42 -42 -45
Total Gross Profit		 42 59 95 20 37 21 1.95 1.61 1.30 0.88 0.90
Total Revenue		 42 59 95 20 37 21 1.95 1.61 1.30 0.88 0.90
Operating Revenue		 42 59 95 20 37 21 1.95 1.61 1.30 0.88 0.90
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 37 38 41 41 43 42 49 49 44 43 46
Selling, General & Admin Expense		 8.65 9.40 9.24 9.97 9.86 10 11 10 9.55 10 10
Research & Development Expense		 28 29 32 31 33 32 38 38 34 33 35
Total Other Income / (Expense), net		 4.29 4.21 4.37 5.77 5.13 4.44 3.92 3.57 3.14 2.62 2.24
Interest Expense		 - - - - - -4.44 -3.92 - - -2.62 -2.24
Income Tax Expense		 19 1.83 2.76 -1.86 -1.87 0.00 0.18 0.65 0.09 0.04 0.04
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - -0.48 0.04 - - 0.41 0.18
Basic Earnings per Share		 ($0.28) $0.70 $1.61 ($0.35) ($0.20) ($0.42) ($1.04) ($1.06) ($0.95) ($0.95) ($1.01)
Weighted Average Basic Shares Outstanding		 33.05M 33.50M 34.18M 40.63M 37.31M 41.07M 41.34M 41.46M 41.37M 41.84M 42.22M
Diluted Earnings per Share		 ($0.23) $0.68 $1.55 ($0.35) ($0.20) ($0.42) ($1.04) ($1.06) ($0.95) ($0.95) ($1.01)
Weighted Average Diluted Shares Outstanding		 33.05M 34.79M 35.51M 40.63M 39.00M 41.07M 41.34M 41.46M 41.37M 41.84M 42.22M
Weighted Average Basic & Diluted Shares Outstanding		 33.60M 33.76M 37.20M 37.42M 37.59M 37.95M 38.04M 38.22M 38.28M 38.82M 38.94M

Annual Cash Flow Statements for Entrada Therapeutics

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 22 252 -242 22 34 -11
Net Cash From Operating Activities		 -26 -51 -94 140 -42 -129
Net Cash From Continuing Operating Activities		 -26 -51 -94 140 -42 -129
Net Income / (Loss) Continuing Operations		 -27 -51 -95 -6.69 66 -144
Consolidated Net Income / (Loss)		 -27 -51 -95 -6.69 66 -144
Depreciation Expense		 0.33 1.12 1.90 2.84 3.77 4.10
Amortization Expense		 - 0.00 0.15 -5.78 -10 -3.67
Non-Cash Adjustments To Reconcile Net Income		 0.35 2.60 18 13 18 30
Changes in Operating Assets and Liabilities, net		 0.28 -3.42 -19 136 -119 -15
Net Cash From Investing Activities		 -2.32 -4.58 -149 -138 -28 117
Net Cash From Continuing Investing Activities		 -2.32 -4.58 -149 -138 -28 117
Purchase of Property, Plant & Equipment		 -2.32 -4.58 -2.89 -5.61 -3.16 -1.04
Purchase of Investments		 - 0.00 -222 -407 -438 -142
Sale and/or Maturity of Investments		 - 0.00 76 274 413 259
Net Cash From Financing Activities		 50 307 0.48 21 103 0.89
Net Cash From Continuing Financing Activities		 50 307 0.48 21 103 0.89
Issuance of Common Equity		 0.00 191 0.20 21 100 0.46
Other Financing Activities, net		 0.25 0.94 0.28 - 2.78 0.43
Cash Income Taxes Paid		 - - 0.00 15 4.62 1.70

Quarterly Cash Flow Statements for Entrada Therapeutics

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 16 0.83 117 -107 23 -33 4.65 21 -2.89 -15 23
Net Cash From Operating Activities		 -4.01 -26 40 -24 -32 -39 -29 -28 -32 -42 -32
Net Cash From Continuing Operating Activities		 -4.01 -26 40 -24 -32 -39 -29 -28 -32 -42 -32
Net Income / (Loss) Continuing Operations		 -9.54 23 55 -14 1.13 -17 -43 -44 -39 -40 -43
Consolidated Net Income / (Loss)		 -9.54 23 55 -14 1.13 -17 -43 -44 -39 -40 -43
Depreciation Expense		 0.74 0.93 0.91 0.94 0.99 0.95 1.03 1.23 0.89 0.81 0.84
Amortization Expense		 -2.00 -2.04 -2.26 -3.21 -2.51 -1.34 -0.96 -0.74 -0.63 -0.55 -0.45
Non-Cash Adjustments To Reconcile Net Income		 3.84 3.73 4.62 4.86 4.70 5.09 5.05 5.12 15 4.74 5.15
Changes in Operating Assets and Liabilities, net		 2.95 -52 -18 -13 -36 -26 8.49 10 -8.32 -6.98 4.76
Net Cash From Investing Activities		 19 26 -24 -83 53 4.78 34 49 29 27 55
Net Cash From Continuing Investing Activities		 19 26 -24 -83 53 4.78 34 49 29 27 55
Purchase of Property, Plant & Equipment		 -0.98 -0.84 -1.05 -0.64 -0.64 -1.14 -0.28 0.17 0.21 -0.04 -0.01
Purchase of Investments		 -89 -97 -111 -166 -64 -80 -17 -27 -18 -12 -3.93
Sale and/or Maturity of Investments		 109 124 87 83 118 86 51 76 47 39 59
Net Cash From Financing Activities		 0.69 0.21 101 -0.01 1.40 0.35 0.34 0.01 0.19 0.10 0.35
Net Cash From Continuing Financing Activities		 0.69 0.21 101 -0.01 1.40 0.35 0.34 0.01 0.19 0.10 0.35
Other Financing Activities, net		 - 0.21 1.10 0.38 - 0.35 0.02 0.01 0.05 0.10 0.03

Annual Balance Sheets for Entrada Therapeutics

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 44 306 252 469 526 377
Total Current Assets		 40 299 210 370 440 306
Cash & Equivalents		 39 291 45 68 101 90
Restricted Cash		 - - - - 0.00 0.66
Short-Term Investments		 - 0.00 144 284 319 205
Prepaid Expenses		 0.90 7.64 21 12 16 8.72
Other Current Assets		 - - 0.00 5.88 3.68 1.18
Plant, Property, & Equipment, net		 3.04 6.26 7.68 11 11 7.31
Total Noncurrent Assets		 0.54 0.87 35 88 75 64
Other Noncurrent Operating Assets		 0.54 0.87 35 88 75 64
Total Liabilities & Shareholders' Equity		 44 306 252 469 526 377
Total Liabilities		 3.36 7.12 40 227 98 71
Total Current Liabilities		 3.36 6.72 22 159 39 24
Accounts Payable		 1.60 0.71 5.99 3.28 4.26 2.29
Accrued Expenses		 1.76 6.01 7.58 11 13 18
Current Deferred Revenue		 - - 0.00 132 14 0.34
Other Current Liabilities		 - 0.00 - 7.91 7.56 4.14
Total Noncurrent Liabilities		 0.00 0.40 18 68 58 47
Other Noncurrent Operating Liabilities		 - 0.00 18 60 52 47
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -41 299 213 242 429 306
Total Preferred & Common Equity		 -41 299 213 242 429 306
Total Common Equity		 -41 299 213 242 429 306
Common Stock		 1.02 392 403 437 558 579
Retained Earnings		 -43 -94 -188 -195 -129 -273
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -2.06 0.20 -0.04 0.65

Quarterly Balance Sheets for Entrada Therapeutics

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 476 494 485 511 582 555 486 449 413 336 299
Total Current Assets		 434 390 383 414 490 465 403 369 338 267 233
Cash & Equivalents		 228 80 52 68 185 78 68 72 93 76 99
Restricted Cash		 - - - - - - - - - 0.00 0.00
Short-Term Investments		 184 297 302 259 284 371 315 282 234 178 124
Prepaid Expenses		 16 9.66 24 9.24 12 13 19 14 10 11 8.88
Other Current Assets		 6.30 3.74 5.03 78 7.67 2.60 2.04 1.18 1.20 0.79 0.82
Plant, Property, & Equipment, net		 9.39 11 11 11 11 11 11 9.81 8.41 6.51 5.72
Total Noncurrent Assets		 32 93 91 86 81 78 73 70 66 62 60
Other Noncurrent Operating Assets		 32 93 91 86 81 78 73 70 66 62 60
Total Liabilities & Shareholders' Equity		 476 494 485 511 582 555 486 449 413 336 299
Total Liabilities		 246 287 238 241 152 132 69 69 72 65 65
Total Current Liabilities		 148 126 165 174 86 71 18 20 24 19 21
Accounts Payable		 6.47 2.42 0.75 2.53 1.64 1.29 2.19 1.86 3.17 2.93 3.75
Accrued Expenses		 12 7.11 9.60 8.79 11 13 7.58 12 16 12 13
Current Deferred Revenue		 122 102 148 148 60 46 1.35 0.69 0.35 0.25 0.17
Other Current Liabilities		 7.10 7.41 6.64 8.30 8.57 - 6.51 - 4.35 - 4.45
Total Noncurrent Liabilities		 98 161 73 68 66 62 51 49 48 45 44
Other Noncurrent Operating Liabilities		 9.12 66 62 58 56 - 50 - 48 - 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 230 207 247 269 430 422 417 380 341 271 233
Total Preferred & Common Equity		 230 207 247 269 430 422 417 380 341 271 233
Total Common Equity		 230 207 247 269 430 422 417 380 341 271 233
Common Stock		 425 429 433 441 547 552 564 569 574 583 589
Retained Earnings		 -195 -221 -185 -171 -116 -130 -147 -190 -234 -313 -356
Accumulated Other Comprehensive Income / (Loss)		 -0.64 -1.01 -0.50 -0.25 -0.33 0.97 0.44 0.40 0.62 0.25 0.07

Annual Metrics And Ratios for Entrada Therapeutics

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 31,212,856.00 - - - 38,219,232.00
DEI Adjusted Shares Outstanding		 0.00 31,212,856.00 - - - 38,219,232.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.64 - - - -3.74
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 63.38% -87.94%
EBITDA Growth		 0.00% -91.02% -84.99% 109.85% 560.67% -486.29%
EBIT Growth		 0.00% -92.88% -84.95% 112.74% 451.47% -435.87%
NOPAT Growth		 0.00% -91.72% -90.21% 102.58% 2,546.62% -338.19%
Net Income Growth		 0.00% -92.88% -84.95% 92.93% 1,081.69% -319.04%
EPS Growth		 0.00% 66.00% 62.99% 93.38% 940.00% -306.55%
Operating Cash Flow Growth		 0.00% -98.91% -84.39% 249.07% -129.73% -209.24%
Free Cash Flow Firm Growth		 0.00% 0.00% -118.97% 254.97% -155.32% -55.28%
Invested Capital Growth		 0.00% 581.57% 321.32% -439.89% 114.82% 12.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 48.01% -2.07% -58.68%
EBITDA Q/Q Growth		 0.00% 0.00% -7.08% 126.13% 16.32% -48.79%
EBIT Q/Q Growth		 0.00% 0.00% -6.99% 135.83% 15.06% -51.11%
NOPAT Q/Q Growth		 0.00% 0.00% -7.90% 107.44% 11.68% -29.90%
Net Income Q/Q Growth		 0.00% 0.00% -6.99% 69.29% 19.43% -38.95%
EPS Q/Q Growth		 0.00% 0.00% -122.17% 73.68% 1.82% -27.57%
Operating Cash Flow Q/Q Growth		 0.00% -37.67% -7.77% 19.99% -197.58% -0.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 42.17% 20.38% -72.93%
Invested Capital Q/Q Growth		 0.00% 0.00% 82.73% -2.52% -52.82% -29.55%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 7.07% 28.58% -619.46%
Operating Margin		 0.00% 0.00% 0.00% -2.45% 22.30% -621.13%
EBIT Margin		 0.00% 0.00% 0.00% 9.34% 31.54% -621.13%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -5.18% 31.13% -565.48%
Tax Burden Percent		 100.55% 100.00% 100.00% -55.45% 98.71% 100.65%
Interest Burden Percent		 99.46% 100.00% 100.00% 100.00% 100.00% 90.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 155.45% 1.29% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,197.69%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -1,188.41%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 1,158.56%
Return on Equity (ROE)		 -66.03% -30.19% -37.01% -2.94% 19.56% -39.13%
Cash Return on Invested Capital (CROIC)		 0.00% -964.34% -464.48% 0.00% -489.22% -1,209.57%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 3.34% 13.36% -34.94%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -1.85% 13.18% -31.81%
Return on Common Equity (ROCE)		 68.20% -22.92% -37.01% -2.94% 19.56% -39.13%
Return on Equity Simple (ROE_SIMPLE)		 63.93% -17.13% -44.51% -2.76% 15.31% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -36 -68 1.75 46 -111
NOPAT Margin		 0.00% 0.00% 0.00% 1.36% 22.02% -434.79%
Net Nonoperating Expense Percent (NNEP)		 -20.12% -9.31% -11.26% -3.17% 5.03% -9.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 0.72% 10.64% -36.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 25.03% 18.25% 161.48%
R&D to Revenue		 0.00% 0.00% 0.00% 77.42% 59.45% 559.65%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 102.45% 77.70% 721.13%
Earnings before Interest and Taxes (EBIT)		 -27 -51 -95 12 66 -158
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -50 -93 9.12 60 -157
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.79 2.00 2.08 1.51 1.28
Price to Tangible Book Value (P/TBV)		 0.00 1.79 2.00 2.08 1.51 1.28
Price to Revenue (P/Rev)		 0.00 0.00 0.00 3.90 3.07 15.46
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 9.86 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 10.14% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 199.57 31.79 7.58 0.00 14.44 9.87
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 1.17 1.11 3.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 16.62 3.89 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 12.57 3.53 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 86.44 5.05 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 1.08 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 1.06 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.04 0.00 0.02 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.97 -0.92 -1.17 -1.14 -0.97
Leverage Ratio		 1.08 1.03 1.09 1.59 1.48 1.23
Compound Leverage Factor		 1.08 1.03 1.09 1.59 1.48 1.11
Debt to Total Capital		 0.00% 0.00% 3.80% 0.00% 1.73% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 3.80% 0.00% 1.73% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 203.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -103.29% 100.00% 96.20% 100.00% 98.27% 100.00%
Debt to EBITDA		 0.00 0.00 -0.09 0.00 0.13 0.00
Net Debt to EBITDA		 0.00 0.00 1.95 0.00 -6.85 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.12 0.00 0.16 0.00
Net Debt to NOPAT		 0.00 0.00 2.65 0.00 -8.89 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 30.05 45.23 5.06 1.65 5.36 1.88
Noncontrolling Interest Sharing Ratio		 203.29% 24.10% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 11.89 44.46 9.55 2.33 11.15 12.53
Quick Ratio		 11.62 43.32 8.59 2.22 10.64 12.09
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -42 -93 144 -79 -112
Operating Cash Flow to CapEx		 -1,103.11% -1,110.52% -3,248.56% 2,490.26% -1,315.93% -12,345.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.36 0.42 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 13.67 19.06 2.79
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 1.12 7.65 32 -110 16 9.78
Invested Capital Turnover		 0.00 0.00 0.00 -3.34 -4.52 2.75
Increase / (Decrease) in Invested Capital		 0.00 6.53 25 -142 126 1.10
Enterprise Value (EV)		 224 243 244 152 235 97
Market Capitalization		 182 534 425 504 647 393
Book Value per Share		 ($37.54) $9.57 $6.77 $7.26 $11.46 $8.01
Tangible Book Value per Share		 ($37.54) $9.57 $6.77 $7.26 $11.46 $8.01
Total Capital		 40 299 221 242 436 306
Total Debt		 0.00 0.00 8.41 0.00 7.56 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -39 -291 -180 -352 -412 -296
Capital Expenditures (CapEx)		 2.32 4.58 2.89 5.61 3.16 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.46 0.92 7.60 -141 -12 -15
Debt-free Net Working Capital (DFNWC)		 37 292 196 211 408 282
Net Working Capital (NWC)		 37 292 188 211 401 282
Net Nonoperating Expense (NNE)		 7.86 15 27 8.44 -19 33
Net Nonoperating Obligations (NNO)		 -39 -291 -180 -352 -412 -296
Total Depreciation and Amortization (D&A)		 0.33 1.12 2.05 -2.94 -6.25 0.43
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -109.29% -5.64% -57.26%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 163.53% 193.62% 1,108.54%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 163.53% 190.03% 1,108.54%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.16) ($3.02) ($0.20) $1.76 ($3.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 6.27M 31.29M 33.05M 37.31M 41.37M
Adjusted Diluted Earnings per Share		 $0.00 ($8.16) ($3.02) ($0.20) $1.68 ($3.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 6.27M 31.29M 33.05M 39.00M 41.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 31.25M 33.08M 33.60M 37.59M 38.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -36 -68 -2.21 46 -111
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -1.72% 22.02% -434.79%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 9.34% 31.54% -561.84%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Entrada Therapeutics

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 37,594,630.00 37,953,417.00 38,037,079.00 38,219,232.00 38,284,313.00 38,820,616.00
DEI Adjusted Shares Outstanding		 - - - - - 37,594,630.00 37,953,417.00 38,037,079.00 38,219,232.00 38,284,313.00 38,820,616.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.45 -1.14 -1.16 -1.01 -1.05 -1.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 134.05% 421.16% -55.25% -10.63% -65.23% -97.94% -91.75% -96.53% -95.74% -53.95%
EBITDA Growth		 115.05% 959.31% 426.99% -206.59% -161.89% -191.57% -175.93% -136.62% -468.34% -89.55% 4.71%
EBIT Growth		 119.92% 910.98% 454.56% -187.98% -115.07% -186.03% -174.28% -173.60% -619.41% -94.14% 4.03%
NOPAT Growth		 71.57% 584.10% 545.89% -155.11% 19.32% -177.87% -164.46% -117.25% -619.41% -94.14% 4.03%
Net Income Growth		 61.25% 452.05% 312.25% -139.57% 111.85% -173.84% -178.32% -214.52% -3,562.78% -128.93% 0.79%
EPS Growth		 70.89% 423.81% 298.72% -134.31% 13.04% -161.76% -167.10% -202.86% -375.00% -126.19% 2.88%
Operating Cash Flow Growth		 85.30% -112.55% 213.51% 0.92% -687.57% -50.90% -174.03% -16.68% -1.89% -8.28% -10.09%
Free Cash Flow Firm Growth		 421.81% -154.52% -146.51% -202.91% -195.02% -3.51% -93.03% 92.08% 74.96% 43.90% 125.09%
Invested Capital Growth		 -439.89% 68.11% 76.56% 132.19% 114.82% 159.86% 301.49% -59.68% 12.64% 89.22% -87.03%
Revenue Q/Q Growth		 -4.31% 41.27% 60.17% -79.33% 91.10% -45.03% -90.51% -17.23% -19.52% -32.64% 2.63%
EBITDA Q/Q Growth		 -78.63% 565.13% 132.98% -132.19% 87.59% -200.49% -141.54% -0.32% 2.41% -0.22% -6.01%
EBIT Q/Q Growth		 -72.85% 416.35% 128.17% -127.50% 95.35% -271.40% -147.42% -1.29% 2.93% -0.23% -6.29%
NOPAT Q/Q Growth		 -118.50% 484.80% 159.73% -129.80% 72.91% -271.40% -115.00% -0.43% 10.29% -0.23% -6.29%
Net Income Q/Q Growth		 -126.91% 346.19% 134.21% -125.50% 108.06% -1,633.95% -148.45% -2.39% 11.26% -1.41% -7.67%
EPS Q/Q Growth		 -122.55% 395.65% 127.94% -122.58% 42.86% -110.00% -147.62% -1.92% 10.38% 0.00% -6.32%
Operating Cash Flow Q/Q Growth		 83.62% -535.91% 256.09% -160.92% -30.24% -21.84% 23.42% 3.99% -13.74% -29.48% 22.14%
Free Cash Flow Firm Q/Q Growth		 -10.06% -176.32% 24.14% -97.63% 16.96% 11.73% -41.47% 91.89% -147.18% -97.80% 163.28%
Invested Capital Q/Q Growth		 -2.52% 47.04% 31.40% 186.43% -52.82% 300.29% 130.93% -82.70% -29.55% 572.45% -84.17%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 8.70% 40.97% 59.60% -92.84% -6.03% -107.90% -2,197.54% -2,663.51% -3,229.79% -4,805.26% -4,963.47%
Operating Margin		 11.72% 35.71% 56.42% -110.67% -15.69% -105.99% -2,402.51% -2,915.18% -3,249.27% -4,834.63% -5,007.02%
EBIT Margin		 11.72% 42.84% 61.03% -81.21% -1.98% -105.99% -2,201.28% -2,693.93% -3,249.27% -4,834.63% -5,007.02%
Profit (Net Income) Margin		 -22.81% 39.74% 58.11% -71.70% 3.02% -84.39% -2,210.41% -2,734.45% -3,014.93% -4,539.09% -4,762.03%
Tax Burden Percent		 -103.77% 92.77% 95.23% 88.30% -153.04% 100.00% 100.41% 101.50% 100.24% 100.10% 100.08%
Interest Burden Percent		 187.50% 100.00% 100.00% 100.00% 100.00% 79.62% 100.00% 100.00% 92.57% 93.80% 95.03%
Effective Tax Rate		 203.77% 7.23% 4.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,614.35% -5,198.85% -6,265.35% -386.48% -362.39%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,611.67% -5,195.72% -6,262.66% -383.04% -358.07%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,281.55% 4,866.92% 6,105.36% 327.10% 305.12%
Return on Equity (ROE)		 -2.94% 9.41% 32.80% 16.43% 19.56% 7.22% -332.80% -331.93% -159.99% -59.38% -57.28%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -289.92% -489.22% -254.76% -233.53% -267.32% -1,209.57% -310.26% -118.57%
Operating Return on Assets (OROA)		 4.19% 14.15% 27.16% -33.62% -0.84% -36.61% -339.46% -342.60% -182.80% -67.50% -62.76%
Return on Assets (ROA)		 -8.16% 13.12% 25.86% -29.69% 1.28% -29.15% -340.87% -347.75% -169.62% -63.37% -59.69%
Return on Common Equity (ROCE)		 -2.94% 9.41% 32.80% 16.43% 19.56% 7.22% -332.80% -331.93% -159.99% -59.38% -57.28%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 8.72% 24.29% 13.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.09 20 51 -15 -4.11 -15 -33 -33 -30 -30 -31
NOPAT Margin		 -12.16% 33.13% 53.72% -77.47% -10.98% -74.20% -1,681.76% -2,040.63% -2,274.49% -3,384.24% -3,504.91%
Net Nonoperating Expense Percent (NNEP)		 -1.67% 1.06% 0.98% 0.30% 1.37% -0.59% -2.68% -3.13% -2.69% -3.44% -4.32%
Return On Investment Capital (ROIC_SIMPLE)		 -2.10% - - - -0.94% -3.66% -7.55% -9.67% -9.65% -9.24% -13.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 20.67% 15.90% 9.75% 50.95% 26.36% 49.98% 560.10% 638.41% 735.18% 1,157.03% 1,168.37%
R&D to Revenue		 67.60% 48.39% 33.83% 159.72% 89.33% 156.02% 1,942.41% 2,376.77% 2,614.09% 3,777.60% 3,938.64%
Operating Expenses to Revenue		 88.28% 64.29% 43.58% 210.67% 115.69% 205.99% 2,502.51% 3,015.18% 3,349.27% 4,934.63% 5,107.02%
Earnings before Interest and Taxes (EBIT)		 4.91 25 58 -16 -0.74 -22 -43 -43 -42 -42 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.64 24 56 -18 -2.25 -22 -43 -43 -42 -42 -45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.08 1.77 1.12 1.41 1.51 0.81 0.67 0.65 1.28 1.78 1.22
Price to Tangible Book Value (P/TBV)		 2.08 1.77 1.12 1.41 1.51 0.81 0.67 0.65 1.28 1.78 1.22
Price to Revenue (P/Rev)		 3.90 2.92 2.01 2.76 3.07 1.97 3.21 3.59 15.46 84.20 60.97
Price to Earnings (P/E)		 0.00 18.50 4.51 10.50 9.86 13.58 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 5.41% 22.16% 9.52% 10.14% 7.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 6.00 14.44 0.00 0.00 0.00 9.87 4.23 6.03
Enterprise Value to Revenue (EV/Rev)		 1.17 0.91 0.05 0.96 1.11 0.00 0.00 0.00 3.80 48.46 13.38
Enterprise Value to EBITDA (EV/EBITDA)		 16.62 4.11 0.13 3.99 3.89 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 12.57 3.67 0.12 3.57 3.53 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 86.44 10.81 0.13 4.97 5.05 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 1.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.15 0.02 0.00 0.14 0.00 0.00 0.18 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.13 0.00 0.00 0.13 0.00 0.00 0.17 0.00
Financial Leverage		 -1.17 -1.48 -1.33 -1.11 -1.14 -1.03 -0.95 -0.94 -0.97 -0.85 -0.85
Leverage Ratio		 1.59 1.98 1.69 1.55 1.48 1.45 1.27 1.27 1.23 1.19 1.22
Compound Leverage Factor		 2.97 1.98 1.69 1.55 1.48 1.16 1.27 1.27 1.14 1.12 1.16
Debt to Total Capital		 0.00% 0.00% 0.00% 12.67% 1.73% 0.00% 12.61% 0.00% 0.00% 15.52% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.60% 1.73% 0.00% 1.26% 0.00% 0.00% 1.34% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 11.07% 0.00% 0.00% 11.35% 0.00% 0.00% 14.18% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 87.33% 98.27% 100.00% 87.39% 100.00% 100.00% 84.48% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 1.18 0.13 0.00 -0.68 0.00 0.00 -0.28 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -7.49 -6.85 0.00 3.69 0.00 0.00 1.16 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 1.03 0.00 0.00 -0.61 0.00 0.00 -0.26 0.00
Debt to NOPAT		 0.00 0.00 0.00 1.48 0.16 0.00 -0.81 0.00 0.00 -0.40 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -9.34 -8.89 0.00 4.45 0.00 0.00 1.64 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 1.29 0.00 0.00 -0.73 0.00 0.00 -0.36 0.00
Altman Z-Score		 1.60 1.76 3.19 3.52 4.94 3.68 2.41 1.76 2.89 3.66 1.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.33 2.38 5.70 6.59 11.15 21.88 18.64 14.08 12.53 13.90 10.89
Quick Ratio		 2.22 1.88 5.47 6.36 10.64 20.75 17.88 13.61 12.09 13.28 10.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 137 -104 -79 -156 -130 -108 -153 -12 -31 -61 38
Operating Cash Flow to CapEx		 -411.17% -3,045.23% 3,808.13% -3,797.50% -4,977.17% -3,366.00% -10,723.27% 0.00% 0.00% -94,761.36% -295,118.18%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.36 0.33 0.45 0.41 0.42 0.35 0.15 0.13 0.06 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 13.67 15.97 21.41 19.72 19.06 15.89 7.52 6.41 2.79 0.67 0.60
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -110 -58 -40 34 16 35 80 14 9.78 66 10
Invested Capital Turnover		 -3.34 -1.36 -2.28 -5.94 -4.52 -14.78 3.93 2.55 2.75 0.11 0.10
Increase / (Decrease) in Invested Capital		 -142 124 130 141 126 93 120 -21 1.10 31 -70
Enterprise Value (EV)		 152 149 11 206 235 -43 -44 -106 97 278 63
Market Capitalization		 504 476 481 594 647 340 255 221 393 483 286
Book Value per Share		 $7.26 $8.02 $12.74 $11.36 $11.46 $11.10 $10.00 $8.96 $8.01 $7.07 $6.01
Tangible Book Value per Share		 $7.26 $8.02 $12.74 $11.36 $11.46 $11.10 $10.00 $8.96 $8.01 $7.07 $6.01
Total Capital		 242 269 430 484 436 417 434 341 306 321 233
Total Debt		 0.00 0.00 0.00 61 7.56 0.00 55 0.00 0.00 50 0.00
Total Long-Term Debt		 0.00 0.00 0.00 54 0.00 0.00 49 0.00 0.00 45 0.00
Net Debt		 -352 -327 -470 -388 -412 -383 -299 -327 -296 -205 -223
Capital Expenditures (CapEx)		 0.98 0.84 1.05 0.64 0.64 1.14 0.28 -0.17 -0.21 0.04 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -141 -87 -66 -47 -12 2.25 0.79 -13 -15 -2.90 -12
Debt-free Net Working Capital (DFNWC)		 211 240 404 402 408 385 355 314 282 252 211
Net Working Capital (NWC)		 211 240 404 395 401 385 349 314 282 248 211
Net Nonoperating Expense (NNE)		 4.45 -3.91 -4.16 -1.13 -5.24 2.10 10 11 9.62 10 11
Net Nonoperating Obligations (NNO)		 -352 -327 -470 -388 -412 -383 -299 -327 -296 -205 -223
Total Depreciation and Amortization (D&A)		 -1.26 -1.10 -1.35 -2.28 -1.52 -0.39 0.07 0.49 0.25 0.26 0.39
Debt-free, Cash-free Net Working Capital to Revenue		 -109.29% -53.53% -27.58% -21.78% -5.64% 1.30% 1.00% -20.48% -57.26% -50.56% -249.08%
Debt-free Net Working Capital to Revenue		 163.53% 147.50% 168.64% 186.99% 193.62% 223.41% 446.43% 510.79% 1,108.54% 4,391.04% 4,509.88%
Net Working Capital to Revenue		 163.53% 147.50% 168.64% 183.40% 190.03% 223.41% 439.56% 510.79% 1,108.54% 4,316.43% 4,509.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.28) $0.70 $1.61 ($0.35) ($0.20) ($0.42) ($1.04) ($1.06) ($0.95) ($0.95) ($1.01)
Adjusted Weighted Average Basic Shares Outstanding		 33.05M 33.50M 34.18M 40.63M 37.31M 41.07M 41.34M 41.46M 41.37M 41.84M 42.22M
Adjusted Diluted Earnings per Share		 ($0.23) $0.68 $1.55 ($0.35) ($0.20) ($0.42) ($1.04) ($1.06) ($0.95) ($0.95) ($1.01)
Adjusted Weighted Average Diluted Shares Outstanding		 33.05M 34.79M 35.51M 40.63M 39.00M 41.07M 41.34M 41.46M 41.37M 41.84M 42.22M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 33.60M 33.76M 37.20M 37.42M 37.59M 37.95M 38.04M 38.22M 38.28M 38.82M 38.94M
Normalized Net Operating Profit after Tax (NOPAT)		 3.43 20 51 -15 -4.11 -15 -33 -33 -30 -30 -31
Normalized NOPAT Margin		 8.20% 33.13% 53.72% -77.47% -10.98% -74.20% -1,681.76% -2,040.63% -2,274.49% -3,384.24% -3,504.91%
Pre Tax Income Margin		 21.98% 42.84% 61.03% -81.21% -1.98% -84.39% -2,201.28% -2,693.93% -3,007.85% -4,534.74% -4,758.13%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Entrada Therapeutics’ financial statements show a company with substantial liquidity but continuing development-stage losses. The most recent quarter, Q2 2026, included $898,000 of revenue, a $42.8 million net loss and a $32.5 million operating cash outflow. Revenue remains small and uneven compared with the much higher partnership-related revenue reported in 2024.

  • Liquidity remains a key strength. As of June 30, 2026, Entrada held $99.3 million in cash and $123.7 million in short-term investments, or approximately $223.0 million in liquid assets. This provides a meaningful financial cushion for ongoing research and development.
  • Operating cash burn improved sequentially. Net cash used in operating activities declined to $32.5 million in Q2 2026 from $41.7 million in Q1 2026. The latest burn rate was also broadly in line with Q4 2025 and lower than the $38.5 million used in Q1 2025.
  • The balance sheet has limited near-term debt pressure. Current liabilities were $21.4 million versus $232.7 million of current assets, producing a current ratio of roughly 10.9. The company reported no short-term debt in Q2 2026, although it continues to carry significant noncurrent obligations.
  • Investment management continues to support cash balances. Entrada generated $54.9 million of investing cash flow in Q2 2026, primarily from $58.9 million of investment maturities or sales. This is not recurring operating income, but it demonstrates that the company can convert investments into cash when needed.
  • Research spending remains elevated and relatively consistent. R&D expense was $35.4 million in Q2 2026, up from $33.1 million in Q1 2026 and $33.0 million in Q2 2025. The spending supports pipeline development but has not yet translated into sustainable product revenue.
  • Share count has increased over the longer term. Weighted-average basic shares reached 42.2 million in Q2 2026, compared with 33.5 million in Q1 2024. Recent financing cash flows have been modest, but historical equity issuance has expanded the share base and may limit per-share upside.
  • Revenue has deteriorated sharply from 2024 levels. Quarterly revenue fell from $94.7 million in Q2 2024 and $59.1 million in Q1 2024 to $1.3 million in Q4 2025, $875,000 in Q1 2026 and $898,000 in Q2 2026. The latest results suggest that prior partnership or milestone revenue was not recurring.
  • Losses remain substantial and persistent. Entrada posted net losses attributable to common shareholders of $43.0 million in Q2 2026 and $40.1 million in Q1 2026. Retained earnings declined to negative $355.6 million, reflecting the cumulative impact of ongoing operating losses.
  • The company remains dependent on its cash reserves and investment portfolio. Operating activities have generated negative cash flow in every recent quarter shown, including $32.5 million in Q2 2026. At the latest quarterly burn rate, the approximately $223 million of cash and short-term investments represents roughly seven quarters of coverage before considering investment income, changes in spending or additional financing.
  • Profitability remains distant. Q2 2026 operating expenses totaled $45.9 million against only $898,000 of revenue, resulting in a $45.0 million operating loss. Interest and investment income helped reduce the net loss, but the core business continues to operate well below break-even.

Overall, Entrada’s financial position is supported by a sizable liquid asset base and manageable current liabilities, but the company’s investment case remains highly dependent on clinical progress, future partnerships or other sources of revenue. Investors should closely monitor quarterly cash burn, the conversion of pipeline programs into commercial or milestone revenue, and any future equity financing that could dilute shareholders.

10/16/26 11:44 PM ETAI Generated. May Contain Errors.

Entrada Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Entrada Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Entrada Therapeutics' net income appears to be on a downward trend, with a most recent value of -$143.75 million in 2025, falling from -$26.52 million in 2020. The previous period was $65.63 million in 2024. Find out what analysts predict for Entrada Therapeutics in the coming months.

Entrada Therapeutics' total operating income in 2025 was -$157.90 million, based on the following breakdown:
  • Total Gross Profit: $25.42 million
  • Total Operating Expenses: $183.32 million

Over the last 5 years, Entrada Therapeutics' total revenue changed from $0.00 in 2020 to $25.42 million in 2025, a change of 2,542,100,000.0%.

In the past 13 quarters, Entrada Therapeutics' cash and equivalents has ranged from $51.88 million in Q3 2023 to $227.65 million in Q1 2023, and is currently $99.28 million as of their latest financial filing in Q2 2026.

Entrada Therapeutics had total debt of $0.00 at the end of 2025, a 100.0% decrease from 2024, and none in 2020.

Over the last 5 years, Entrada Therapeutics' book value per share changed from -37.54 in 2020 to 8.01 in 2025.


Related Companies

Financial statements for NASDAQ:TRDA last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Elon Musk’s 4th Wealth Window Set to Open by October 30
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...
Brownstone Research | Sponsoredtc pixel
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...
Weiss Ratings | Sponsoredtc pixel
SpaceX minted 4400 millionaires in a single day
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...
Behind the Markets | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
This high yielding “gold annuity” is starting to move…
Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...
Golden Portfolio | Sponsoredtc pixel